Synthesis and Biological Evaluation of Naphthoquinone Analogs as a Novel Class of Proteasome Inhibitors

Por Lawrence, Harshani R., Kazi, Aslamuzzaman, Luo, Yunting, Kendig, Robert, Ge, Yiyu, Jain, Sanjula, Daniel, Kenyon, Santiago, Daniel, Guida, Wayne C., Sebti, Saïd M.
Publicado em 2010

Effect of Ack1 Tyrosine Kinase Inhibitor on Ligand-Independent Androgen Receptor Activity

Por Mahajan, Kiran, Challa, Sridevi, Coppola, Domenico, Lawrence, Harshani, Luo, Yunting, Gevariya, Harsukh, Zhu, Weiwei, Chen, Y. Ann, Lawrence, Nicholas J., Mahajan, Nupam P.
Publicado em 2010

Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation

Por Yang, Hua, Lawrence, Harshani R., Kazi, Aslamuzzaman, Gevariya, Harsukh, Patel, Ronil, Luo, Yunting, Rix, Uwe, Schonbrunn, Ernst, Lawrence, Nicholas J., Sebti, Said M.
Publicado em 2014

Discovery and Synthesis of Hydronaphthoquinones as Novel Proteasome Inhibitors

Por Ge, Yiyu, Kazi, Aslamuzzaman, Marsilio, Frank, Luo, Yunting, Jain, Sanjula, Brooks, Wesley, Daniel, Kenyon G., Guida, Wayne C., Sebti, Saïd M., Lawrence, Harshani R.
Publicado em 2012

A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A

Por Martin, Mathew P., Zhu, Jin-Yi, Lawrence, Harshani R., Pireddu, Roberta, Luo, Yunting, Alam, Riazul, Ozcan, Sevil, Sebti, Said M., Lawrence, Nicholas J., Schönbrunn, Ernst
Publicado no ACS Chem Biol (2012)

Development of Novel ACK1/TNK2 Inhibitors Using a Fragment-Based Approach

Por Lawrence, Harshani R., Mahajan, Kiran, Luo, Yunting, Zhang, Daniel, Tindall, Nathan, Huseyin, Miles, Gevariya, Harsukh, Kazi, Sakib, Ozcan, Sevil, Mahajan, Nupam P., Lawrence, Nicholas J.
Publicado no J Med Chem (2015)

Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition

Por Phadke, Manali, Remsing Rix, Lily L., Smalley, Inna, Bryant, Annamarie T., Luo, Yunting, Lawrence, Harshani R., Schaible, Braydon J., Chen, Yian A., Rix, Uwe, Smalley, Keiran S. M.
Publicado no Mol Oncol (2017)

GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells

Por Remsing Rix, Lily L., Kuenzi, Brent M., Luo, Yunting, Remily-Wood, Elizabeth, Kinose, Fumi, Wright, Gabriela, Li, Jiannong, Koomen, John M., Haura, Eric B., Lawrence, Harshani R., Rix, Uwe
Publicado em 2013

Dual targeting of WEE1 and PLK1 by AZD1775 elicits single agent cellular anticancer activity

Por Wright, Gabriela, Golubeva, Volha, Remsing Rix, Lily L., Berndt, Norbert, Luo, Yunting, Ward, Grace A., Gray, Jhanelle E., Schonbrunn, Ernst, Lawrence, Harshani R., Monteiro, Alvaro N.A., Rix, Uwe
Publicado no ACS Chem Biol (2017)

Inhibitors of Src Homology-2 Domain containing Protein Tyrosine Phosphatase-2 (Shp2) Based on Oxindole Scaffolds

Por Lawrence, Harshani R., Pireddu, Roberta, Chen, Liwei, Luo, Yunting, Sung, Shen-Shu, Szymanski, Ann Marie, Richard Yip, M. L., Guida, Wayne C., Sebti, Saïd M., Wu, Jie, Lawrence, Nicholas J.
Publicado em 2008

Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112

Por Chen, Liwei, Pernazza, Daniele, Scott, Latanya M., Lawrence, Harshani R., Ren, Yuan, Luo, Yunting, Wu, Xin, Sung, Shen-Shu, Guida, Wayne C., Sebti, Said M., Lawrence, Nicholas J., Wu, Jie
Publicado em 2010

Proteome-wide profiling of clinical PARP inhibitors reveals compound-specific secondary targets

Por Knezevic, Claire E., Wright, Gabriela, Rix, Lily L. Remsing, Kim, Woosuk, Kuenzi, Brent M., Luo, Yunting, Watters, January M., Koomen, John M., Haura, Eric B., Monteiro, Alvaro N., Radu, Caius, Lawrence, Harshani R., Rix, Uwe
Publicado no Cell Chem Biol (2016)

Development of ortho-Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors

Por Lawrence, Harshani R., Martin, Matthew P., Luo, Yunting, Pireddu, Roberta, Yang, Hua, Gevariya, Harsukh, Ozcan, Sevil, Zhu, Jin-Yi, Kendig, Robert, Rodriguez, Mercedes, Elias, Roy, Cheng, Jin Q., Sebti, Saïd M., Schonbrunn, Ernst, Lawrence, Nicholas J.
Publicado no J Med Chem (2012)